Uni­ty's ear­ly longevi­ty da­ta look 'en­cour­ag­ing'; Adap­tive Biotech­nolo­gies looks to raise $200M in IPO

→ Bob Nelsen-backed longevi­ty start­up Uni­ty $UBX on Tues­day un­veiled the first ever in-hu­man da­ta on its drug, UBX0101, which is de­signed to de­lay the ag­ing process by snuff­ing senes­cent (old) cells. The first part (A) of the small Phase I study test­ed mul­ti­ple dos­es of the os­teoarthri­tis drug against a place­bo — while the sec­ond por­tion (B) eval­u­at­ed the high­est 4 mg dose of UBX0101 ver­sus a place­bo. The main goal of the study was safe­ty and tol­er­a­bil­i­ty, which was met. In terms of sec­ondary goals such as pain, da­ta from part A were pos­i­tive, with signs of im­prove­ments in pain and func­tion­al scores. Part B re­sults were nu­mer­i­cal­ly su­pe­ri­or in terms of pain and func­tion­al­i­ty, but not deemed sta­tis­ti­cal­ly sig­nif­i­cant. “Our con­clu­sion from the Part A da­ta mea­sure­ments are en­cour­ag­ing… For Part B, we be­lieve more fre­quent dos­ing and longer-term ob­ser­va­tion could lead to im­prove­ments across the pain and func­tion scales,” Can­tor Fitzger­ald an­a­lysts wrote in a note en­ti­tled “Proof Of Con­cept: Check, but More Work is Still to Be Done.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER